The development of such agents which could selectively inhibit SR proteins, thus disturbing the hnRNP/SR balance that appears critical in the regulation of Tat expression and virus production in macrophages, might help control viral rebound from these reservoirs when therapy is interrupted or terminated and increased replication when CD4+ T cells have declined or during opportunistic infections. The gene discussed is TAT; the disease is Opportunistic infection.